Hipec plus chemotherapy and immunotherapy for advanced stomach cancer with peritoneal spread
Part of Cancer, Digestive system clinical trials.
This trial combines heated chemotherapy directly into the abdomen (HIPEC) with standard chemotherapy and an immunotherapy drug to treat advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) and cannot be removed by surgery.
- You have not received any prior cancer treatment for this condition.
- You are in good enough physical condition to be active and carry on daily activities (ECOG score 0 or 1).
- Your vital organs (liver, kidneys, blood cells) are functioning adequately.
- You must be willing to provide blood and tissue samples and follow contraception requirements if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination treatment for stomach cancer that has spread to the lining of the abdomen. It uses a special way to deliver heated chemotherapy directly into the abdomen, along with an immunotherapy drug that helps your immune system attack the cancer.
This trial tests a treatment called HIPEC (heated chemotherapy given directly into the abdomen during surgery) for stomach cancer that has spread to the lining of the belly. The goal is to see if this approach can help remove or shrink the cancer and improve outcomes.
This study tests whether a specialized surgery called HIPEC (heat-treated chemotherapy placed in the belly) can improve outcomes for people with advanced stomach cancer that has reached the lining of the abdomen. It’s given after you’ve already had standard chemotherapy, aiming to better control disease in the belly.
This trial tests combining standard chemotherapy and immunotherapy (tirelizumab) with heated chemotherapy given directly into the belly. It aims to treat stomach cancer that has spread to the abdominal lining, and may help shrink or control the cancer.
This trial compares standard laparoscopic surgery for stomach cancer versus the same surgery plus HIPEC, which is heated chemotherapy placed in the abdomen during the operation. It aims to see if adding the heated chemotherapy improves outcomes for people with higher-stage stomach cancer.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
Hear when a new Peritoneal Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.